Page last updated: 2024-11-05

n-butoxyethanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

n-Butoxyethanol, also known as butyl cellosolve, is a colorless liquid with a mild, sweet odor. It is a solvent commonly used in industrial applications, including paints, varnishes, lacquers, and cleaning products. It is synthesized by the reaction of ethylene oxide with n-butanol. n-Butoxyethanol is a readily absorbed chemical through the skin and can cause skin and eye irritation. It has been linked to adverse health effects, including reproductive problems, neurotoxicity, and developmental toxicity. Due to its widespread use and potential health risks, n-Butoxyethanol has been extensively studied to understand its toxicokinetics, metabolism, and effects on various biological systems.'

n-butoxyethanol: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-butoxyethanol : A primary alcohol that is ethanol in which one of the methyl hydrogens is replaced by a butoxy group. A high-boiling (171degreeC) colourless liquid, it is used as a solvent for paints and inks, as well as in some dry cleaning solutions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8133
CHEMBL ID284588
CHEBI ID63921
SCHEMBL ID15712
MeSH IDM0067557

Synonyms (146)

Synonym
AKOS009028760
LS-13220
smr001253761
MLS002174253
EN300-19317
2-butoxyethan-1-ol
2-butoxy-ethanol
o-butyl ethylene glycol
butyl glycol
monobutyl ether of ethylene glycol
ethylene glycol butyl ether
bucs
glycol monobutyl ether
2-butoxy-1-ethanol
monobutyl glycol ether
111-76-2
ethylene glycol monobutyl ether
nsc60759
n-butoxyethanol
glycol butyl ether
butoxyethanol
wln: q2o4
2-butoxy-aethanol
2-butoxyethanol
butoksyetylowy alkohol
butyglycol(french, german)
butyl oxitol
dowanol eb
ethylene glycol n-butyl ether
ethanol, 2-butoxy-
3-oxa-1-heptanol
2-butossi-etanolo
gafcol eb
.beta.-butoxyethanol
nsc-60759
butyl cellosolve
egbe
butoksyetylowy alkohol [polish]
2-butoxy ethanol (ethylene glycol monobutyl ether)
hsdb 538
un2369
2-n-butoxy-1-ethanol
ektasolve eb solvent
g lycol ether eb
2-butoxy-aethanol [german]
glycol ether eb
ektasolve eb
glycol ether eb acetate
ai3-09903
egmbe
ai3-0993
chimec nr
ccris 5985
ethylene glycol monobutyl ether (egbe)(2-butoxyet)
caswell no. 121
2-butoxy ethanol
butylglycol [french,german]
brn 1732511
ethylene glycol, monobutyl ether
ek tasolve eb solvent
beta-butoxyethanol
ethylene glycol mono butyl ether
butyl cellu-sol
jeffersol eb
nsc 60759
2-butossi-etanolo [italian]
einecs 203-905-0
monobutyl ethylene glycol ether
ethylene glycol mono-n-butyl ether
butylcelosolv [czech]
2-n-butoxyethanol
n-butyl cellosolve
eter monobutilico del etilenglicol [spanish]
butoxyethanol, 2-
epa pesticide chemical code 011501
ether monobutylique de l'ethyleneglycol [french]
NCGC00090683-01
2-butoxyethanol (ethylene glycol monobutyl ether)
NCGC00090683-02
ethylene glycol butyl ether, 99%
NCGC00090683-03
9004-77-7
n-butoxyethanol sodium salt
butylcellosolve
ethyleneglycol monobutyl ether
B0698
CHEMBL284588
chebi:63921 ,
MLS002454362
QSPL 003
NCGC00090683-05
NCGC00090683-04
C19355
cas-111-76-2
tox21_300123
dtxcid904097
tox21_202399
NCGC00254083-01
dtxsid1024097 ,
NCGC00259948-01
unii-i0p9xez9wv
ethylene glycol monobutyl ether [un2369] [keep away from food]
ec 203-905-0
eter monobutilico del etilenglicol
i0p9xez9wv ,
butylcelosolv
ether monobutylique de l'ethyleneglycol
butylglycol
FT-0626297
ec 500-012-0
buoch2ch2oh
2-hydroxyethyl n-butyl ether
2-butoxyethan(ol-d)
2-butoxyethanol [vandf]
2-butoxyethanol [iarc]
butyl monoether glycol
ethylene glycol mono-n-butyl ether [hsdb]
butyl cellosolve [mi]
butoxyethanol [inci]
SCHEMBL15712
minex bdh
butyl 2-hydroxyethyl ether
butyl icinol
butyglycol
2 -butoxyethanol
3-oxaheptan-1-ol
ether alcohol
2-(n-butoxy)ethanol
J-508565
mfcd00002884
ethylene glycol butyl ether, saj first grade, >=99.0%
ethylene glycol butyl ether, spectrophotometric grade, >=99.0%
ethylene glycol butyl ether, analytical standard
ethylene glycol butyl ether, >=99%
ethylene glycol butyl ether, for synthesis, 99.0%
ethyleneglycol-monobutyl ether
ethylene glycol-monobutyl ether
2-butoxy-aethanol(german)
eb solvent
butyloxitol
2-butoxyethanol (butyl cellosolve)
2-butoxy(ethanol-13c2)
aethylenglycolmonobuthylaether
Q421557
2-(1-butyloxy) ethanol
2-butoxyethanol--d4

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" EGBE was toxic at the high (2%) and mid dose (1%) to adult F0 female mice: 13 out of 22 females at the high dose and 6 out of 20 at the mid dose died during the cohabitation period."( Assessment of ethylene glycol monobutyl and monophenyl ether reproductive toxicity using a continuous breeding protocol in Swiss CD-1 mice.
Gulati, DK; Heindel, JJ; Lamb, JC; Lawton, AD; Reel, JR; Russell, VS, 1990
)
0.28
" Ethylene glycol monoethyl ether (EGEE) produced embryo lethality and malformations, and decreased fetal weight at a dose level which was not maternally toxic in the teratology probe."( A comparison of developmental toxicity evident at term to postnatal growth and survival using ethylene glycol monoethyl ether, ethylene glycol monobutyl ether and ethanol.
Lewis, SC; Traul, KA; Wier, PJ, 1987
)
0.27
" The most significant toxic effects produced by EGBE were on the red blood cells including a significant dose-dependent decrease in hemoglobin concentration, red blood cell counts, and mean corpuscular hemoglobin concentration."( Subchronic oral toxicity of ethylene glycol monobutyl ether in male rats.
Krasavage, WJ, 1986
)
0.27
" In view of recent findings with other chemically related glycol ethers, particular attention has been given to possible adverse effects on blood and testicular tissue."( Acute and subchronic toxicity of ethylene glycol monobutyl ether.
Tyler, TR, 1984
)
0.27
" Recently-conducted acute toxicity studies in the guinea pig resulted in an acute oral LD50 of 1400 mg/kg, an acute percutaneous LD50 of greater than 2000 mg/kg, and a 1-hr LC50 greater than 633 ppm."( Acute toxicity of ethylene glycol mono-n-butyl ether in the guinea pig.
Boatman, RJ; Gingell, R; Lewis, S,
)
0.13
" In the present work, we examined potential adverse effects of EGEs on some selected brain structures."( Potential neurotoxic effect of ethylene glycol ethers mixtures.
Budziszewska, B; Krzyżanowska, W; Pomierny, B; Pomierny-Chamioło, L; Regulska, M; Smaga, I; Starek, A; Starek-Swiechowicz, B, 2013
)
0.39
"The obtained results suggested that EGEs exerted adverse effects on the CNS cells and may contribute in pathogenesis of neurodegenerative disorders."( Potential neurotoxic effect of ethylene glycol ethers mixtures.
Budziszewska, B; Krzyżanowska, W; Pomierny, B; Pomierny-Chamioło, L; Regulska, M; Smaga, I; Starek, A; Starek-Swiechowicz, B, 2013
)
0.39
" Guinea pigs showed no adverse effects when exposed for 4 h to the maximum attainable concentration of pure 2-butoxyethanol vapour."( The acute vapour inhalation toxicity of 2-butoxyethanol. Points considered when designing and conducting a study in Guinea pigs and evaluating existing inhalation toxicity data on low volatility solvents.
Kelsey, JR; Otter, R; Rogers, E; Salthammer, T, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The arterial blood concentration of 2-butoxyethanol (ethylene glycol monobutyl ether) was simulated in a physiologically based pharmacokinetic model developed for a 70-kg man."( Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man.
Johanson, G, 1986
)
0.27
"A physiologically based pharmacokinetic model was developed to describe the disposition of 2-butoxyethanol (CAS 111-76-2) and its major metabolite, 2-butoxyacetic acid, in rats and humans."( Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans.
Bormett, GA; Corley, RA; Ghanayem, BI, 1994
)
0.29
" The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model describing the toxicokinetic behavior of 2BE and 2BAA in different species following repeated, long-term exposures."( Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol.
Chou, BJ; Dill, JA; Lee, KM; Roycroft, JH, 1998
)
0.3
" In the pharmacokinetic study, BE and, to a lesser extent, BAA was eliminated more slowly from the forestomach tissue of mice than from blood or other tissues, following either oral gavage or ip injection."( Mode of action and pharmacokinetic studies of 2-butoxyethanol in the mouse with an emphasis on forestomach dosimetry.
Corley, RA; Mast, TJ; Miller, RA; Poet, TS; Soelberg, JJ; Thrall, BD; Weitz, KK, 2003
)
0.32
"A physiologically based pharmacokinetic (PBPK) model describing the disposition of 2-butoxyethanol (2-BE) was developed in order to predict the urinary concentration of its major metabolite, butoxyacetic acid (BAA) under a range of exposure scenarios."( Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol.
Cocker, J; Franks, SJ; Loizou, GD; Spendiff, MK, 2006
)
0.33
"The World Health Organization (WHO) International Programme on Chemical Safety (IPCS) Guidance on Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment (IPCS, 2010) describes key principles for risk assessors and model developers."( Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.
Barton, HA; Bessems, JG; Krishnan, K; Lipscomb, JC; Meek, ME, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" A tendency towards increased percutaneous absorption rate was seen in the raised temperature and humidity condition."( Percutaneous absorption of 2-butoxyethanol vapour in human subjects.
Boman, A; Johanson, G, 1991
)
0.28
"The percutaneous absorption rate and elimination kinetics of 2-butoxyethanol (ethylene glycol monobutyl ether) were estimated in the guinea pig."( Percutaneous uptake rate of 2-butoxyethanol in the guinea pig.
Fernström, P; Johanson, G, 1986
)
0.27
" The model explained the change of profiles of urinary metabolites in different exposure routes by taking into account the differences in absorption rate and by incorporating a minor pathway for metabolism by skin."( Physiologically based modeling of 2-butoxyethanol disposition in rats following different routes of exposure.
Birnbaum, LS; Henderson, RF; Medinsky, MA; Sabourin, PJ; Shyr, LJ, 1993
)
0.29
" The results show that glycol ethers are very well absorbed through the skin."( Occupational chronic exposure to organic solvents. XIV. Examinations concerning the evaluation of a limit value for 2-ethoxyethanol and 2-ethoxyethyl acetate and the genotoxic effects of these glycol ethers.
Angerer, J; Letzel, S; Rüdiger, HW; Söhnlein, B; Weltle, D, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Current studies were undertaken to investigate the effect of repetitive daily dosing of BE on the hematologic parameters of male F344 rats."( Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms.
Ghanayem, BI; Matthews, HB; Sanchez, IM, 1992
)
0.28
" Both male and female mice were dosed for 7 days prior to and during a 98-day cohabitation period."( Assessment of ethylene glycol monobutyl and monophenyl ether reproductive toxicity using a continuous breeding protocol in Swiss CD-1 mice.
Gulati, DK; Heindel, JJ; Lamb, JC; Lawton, AD; Reel, JR; Russell, VS, 1990
)
0.28
" dosing (5 times one injection per hour) with EE (4 mmol/kg) or ME (5 mmol/kg) plus ethanol (8 or 10 mmol/kg) each resulted in an almost complete accumulation of both ether compounds in the blood."( Ethanol-induced accumulation of ethylene glycol monoalkyl ethers in rats.
Balge, F; Freundt, KJ; Römer, KG, 1985
)
0.27
" Data from animal studies have been examined from the standpoint of dose-response relationships and the sensitivity of various animal species, including man, to the effects of this chemical."( Acute and subchronic toxicity of ethylene glycol monobutyl ether.
Tyler, TR, 1984
)
0.27
" Eight female rats received the dosing vehicle (water) and served as controls."( Ocular thrombosis and retinal degeneration induced in female F344 rats by 2-butoxyethanol.
Ghanayem, BI; Maronpot, RR; Nyska, A, 1999
)
0.3
" In this study effects on red blood cell morphology of dosing rats with 2-BE by gavage were compared with the effects of incubation of rat erythrocytes in vitro with the principal metabolite of 2-BE, butoxyacetic acid (BAA)."( Rat erythrocyte morphological changes after gavage dosing with 2-butoxyethanol: a comparison with the in vitro effects of butoxyacetic acid on rat and human erythrocytes.
Udden, MM,
)
0.13
" These morphological changes became progressively more severe as BE dosing continued and included the occasional occurrence of schistocytes and ghost cells, rouleaux formation in rats of both sexes, and an increased number of red blood cells with micronuclei in female rats."( Hemolytic anemia, thrombosis, and infarction in male and female F344 rats following gavage exposure to 2-butoxyethanol.
Chanas, B; Ghanayem, BI; Long, PH; Nyska, A; Nyska, M; Ward, SM, 2001
)
0.31
" Evidence of thrombosis and infarction was seen mainly in females dosed more than once with widespread thrombotic crisis after two or three dosing, likely explicable by the more significant morphological changes in erythrocytes and hemolysis observed in this gender."( A chemically induced rat model of hemolysis with disseminated thrombosis.
Ezov, N; Levin-Harrus, T; Mittelman, M; Nyska, A; Nyska, M; Peddada, S; Redlich, M; Shabat, S; Ward, SM; Yedgar, S, 2002
)
0.31
" The skin surface was dosed with 115."( Metabolism of butoxyethanol in excised human skin in vitro.
Traynor, MJ; Wilkinson, SC; Williams, FM, 2008
)
0.35
" To address this concern, Wistar-Han rats were dosed by oral gavage with a non-genotoxic haemolytic agent, 2-butoxyethanol (2-BE)."( Compensatory erythropoiesis has no impact on the outcome of the in vivo Pig-a mutation assay in rats following treatment with the haemolytic agent 2-butoxyethanol.
Ackerman, JI; Coffing, SL; Criswell, K; Dertinger, SD; Dobo, KL; Gunther, WC; Kenyon, MO, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
protic solventA polar solvent that is capable of acting as a hydron (proton) donor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
glycol etherA hydroxyether which contains both an ether and alcohol functional groups. It is one of the most versatile classes of organic solvents which are commonly used in paints, cleaners, adhesives, pharmaceuticals and cosmetics.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency35.48130.025127.9203501.1870AID651751
thyroid stimulating hormone receptorHomo sapiens (human)Potency8.15480.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.40050.000214.376460.0339AID588532; AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.42730.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.64480.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency76.95880.000723.06741,258.9301AID743085
activating transcription factor 6Homo sapiens (human)Potency61.62220.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (17.44)18.7374
1990's47 (27.33)18.2507
2000's55 (31.98)29.6817
2010's32 (18.60)24.3611
2020's8 (4.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.31 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.05%)5.53%
Reviews7 (3.68%)6.00%
Case Studies8 (4.21%)4.05%
Observational0 (0.00%)0.25%
Other173 (91.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]